Role of sentinel node biopsy in breast cancer: a review

Axillary lymph node involvement is still an important predictor of recurrence and survival in breast cancer. Axillary staging was classically done by axillary lymph node dissection (ALND), but the introduction of sentinel lymph node biopsy (SLNB) has led to a progressive and continuing de-escalation in its use. Therefore, SLNB can now be considered the standard procedure for axillary staging in clinically N0 patients. Different studies have also begun to report that a positive sentinel node does not always require ALND, reducing the morbidity derived from this technique. Fears that this sentinel node approach might not be accurate for neoadjuvant chemotherapy have been allayed by several studies showing that post-neoadjuvant SLNB in clinical N0 patients reduces the rate of ALND. This approach benefits from axillary pathological complete response with an acceptable false-negative rate. By contrast, however, cN1 disease still requires that we optimise the technique to reduce the rate of false negatives. Currently, SLNB is the best method for axillary staging in breast cancer, allowing patients to be treated according to risk of recurrence, and with good evidence that morbidity is lower than with other more radical techniques.

Sentinel lymph node biopsy; Breast cancer; Axillary lymph node dissection; Neoadjuvant chemotherapy; Node positive; Macrometastasis; Micrometastasis

[1] Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 106: 4–16.

[2] Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977; 39: 456–466.

[3] Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Journal of Surgical Oncology. 1993; 2: 335–340.

[4] Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of Surgery. 1994; 220: 391–401.

[5] Gallegos-Hernández JF. El ganglio centinela. Concepto y aplicaciones prácticas en oncología. Revista Mexicana de Anestesiologia. 2007; 30: 193–199.

[6] Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Archives of Surgery. 1992; 127: 392–399.

[7] Atalay C. New concepts in axillary management of breast cancer. World Journal of Clinical Oncology. 2014; 5: 895–900.

[8] Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of Clinical Oncology. 2005; 23: 7703–7720.

[9] Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymphnode resection compared with conventional axillary-lymphnode dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncology. 2010; 11: 927–933.

[10] Benitez A, Cortés M, Bajén M, Gasén AR, Sabaté A. Ganglio centinela, ROLL y SNOLL en cáncer de mama. In Soriano, A., Martin, J., Garcia, A., (eds) Medicina nuclear en la práctica clínica (pp. 571–584). 2nd edn. Grupo Aula Médica: Madrid. 2012.

[11] Harlow SP, Weaver DL. sentinel lymph node in breast cancer: Techniques. 2016. Available at: www.uptodate (Accessed: 1 December 2016).

[12] Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 2542–2551.

[13] Zhang X, Li Y, Zhou Y, Mao F, Lin Y, Guan J, et al. Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: a Meta-Analysis. PLoS ONE. 2017; 11: e0155597.

[14] Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: a Meta-analysis. Annals of Surgical Oncology. 2016; 23: 1508–1514.

[15] Manca G, Rubello D, Tardelli E, Giammarile F, Mazzarri S, Boni G, et al. Sentinel Lymph Node Biopsy in Breast Cancer. Clinical Nuclear Medicine. 2016; 41: 126–133.

[16] Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer: American Society of Clinical Oncology Clin-ical Practice Guideline Update. Journal of Clinical Oncology. 2014; 32: 1365–1383.

[17] Mosbah R, Raimond E, Pelissier A, Hocedez C, Graesslin O. Relevance of the sentinel lymph node biopsy in breast multifocal and multicentric cancer. 2015. Available at: http://linkinghub.elsev ier.com/retrieve/pii/S1297958915000983 (Accessed: 12 January 2017).

[18] Maaskant-Braat AJG, Voogd AC, Roumen RMH, Nieuwenhuijzen GAP. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Research and Treatment. 2013; 138: 13–20.

[19] Boughey JC. Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer. Journal of the American Medical Association. 2013; 310: 1455.

[20] Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymphnode biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. The Lancet Oncology. 2013; 14: 609–618.

[21] Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. Journal of Clinical Oncology. 2009; 27: 726–732.

[22] Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Annals of Surgery. 2009; 250: 558–566.

[23] Gentilini O, Cremonesi M, Trifirò G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Annals of Oncology. 2004; 15: 1348–1351.

[24] Rovera F, Chiappa C, Coglitore A, Baratelli GM, Fachinetti A, Marelli M, et al. Management of breast cancer during pregnancy. International Journal of Surgery. 2013; 11: S64–S68.

[25] Seth P Harlow M, Donald L Weaver M. Diagnosis, staging and the role of sentinel lymph node biopsy in the nodal evaluation of breast cancer. 2016. Available at: www.uptodate.com (Accessed: 1 February 2016).

[26] Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinelnode micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncology. 2013; 14: 297–305.

[27] Jafferbhoy S, McWilliams B. Clinical Significance and Management of Sentinel Node Micrometastasis in Invasive Breast Cancer. Clinical Breast Cancer. 2017; 12: 308–312.

[28] Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01):

10- year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology. 2018; 19: 1385–1393.

[29] Szychta P, Westfal B, Maciejczyk R, Smolarz B, Romanowicz H, Krawczyk T, et al. Intraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with onestep nucleic acid amplification assay (OSNA). Archives of Medical Science. 2016; 6: 1239–1246.

[30] Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, et al. Novel Intraoperative Molecular Test for Sentinel Lymph Node Metastases in Patients with Early-Stage Breast Cancer. Journal of Clinical Oncology. 2008; 26: 3338–3345.

[31] Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management - a systematic review. Journal of Clinical Oncology. 2008; 26: 4981–4989.

[32] Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. Journal of the American Medical Association. 1996; 276: 1818–1822.

[33] Thorsen LBJ, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. Journal of Clinical Oncology. 2016; 34: 314–320.

[34] Caudle AS, Smith BD. Do Internal Mammary Nodes Matter? Annals of Surgical Oncology. 2019; 26: 930–932.

[35] Fujii T, Yajima R, Matsumoto A, Yamaki S, Uchida N, Tsutsumi S, et al. Implication of an Intramammary Sentinel Lymph Node in Breast Cancer: is this a True Sentinel Node? a Case Report. Breast Care. 2010; 5: 102–104.

[36] Intra M, Garcia-Etienne CA, Renne G, Trifirò G, Rotmensz N, Gentilini OD, et al. When sentinel lymph node is intramammary. Annals of Surgical Oncology. 2007; 15: 1304–1308.

[37] Pugliese MS, Stempel MM, Cody HS, Morrow M, Gemignani ML. Surgical management of the axilla: do intramammary nodes matter? American Journal of Surgery. 2009; 198: 532–537.

[38] Riogi B, Sripadam R, Barker D, Harris O, Innes H, Chagla L. Management of the axilla following neoadjuvant chemotherapy for breast cancer- a change in practice. Surgeon. 2021; 19: 1–7.

[39] Magnoni F, Veronesi P. Sentinel node biopsy in conservative surgery for breast cancer: a changing role in clinical practice. Minerva Chirurgica. 2020; 75: 386–391.

[40] Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The Risk of Axillary Relapse after Sentinel Lymph Node Biopsy for Breast Cancer is Comparable with that of Axillary Lymph Node Dissection. Annals of Surgery. 2004; 240: 462–471.

[41] van der Ploeg IMC, Nieweg OE, van Rijk MC, Valdés Olmos RA, Kroon BBR. Axillary recurrence after a tumournegative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. European Journal of Surgical Oncology. 2008; 34: 1277–1284.

[42] Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Journal of the National Cancer Institute. 2006; 98: 599–609.

[43] Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinelnode biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet. 1997; 349: 1864–1867.

[44] Kell MR, Burke JP, Barry M, Morrow M. Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Research and Treatment. 2010; 120: 441–447.

[45] Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. New England Journal of Medicine. 2003; 349: 546–553.

[46] Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for nodepositive breast cancer. Journal of Clinical Oncology. 2009; 27: 2946–2953.

[47] Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for nodepositive breast cancer patients: experience from the SEER database. Annals of Surgical Oncology. 2010; 17: 343–351.

[48] Cyr A, Gao F, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA. Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection. Annals of Surgical Oncology. 2012; 19: 3185–3191.

[49] Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of Surgery. 2010; 252: 426–433.

[50] Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Journal of the American Medical Association. 2011; 305: 569–575.

[51] Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancera multicenter validation study. New England Journal of Medicine. 1998; 339: 941–946.

[52] Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. Journal of Clinical Oncology. 2014; 32: 3600–3606.

[53] Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgery. 2016; 264: 413–420.

[54] Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Meta-analysis of nonsentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. British Journal of Surgery. 2004; 91: 1245–1252.

[55] Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 2013; 24: 2206–2223.

[56] Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, openlabel, phase 3 noninferiority trial. Lancet Oncology. 2014; 15: 1303–1310.

[57] Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. Journal of the American Medical Association. 2011; 306: 385–393.

[58] Fisher B, Jeong J, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. New England Journal of Medicine. 2002; 347: 567–575.

[59] Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine. 2002; 347: 1227–1232.

[60] Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locore-gional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. 2012; 133: 831–841.

[61] Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NS-ABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophos-phamide, methotrexate, and fluorouracil. Journal of Clinical Oncology. 1996; 14: 1982–1992.

[62] Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute. 1996; 88: 1529–1542.

[63] Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology. 2011; 29: 3366–3373.

[64] Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, et al. Characteristics and outcomes of sentinel node–positive breast cancer patients after total mastectomy without axillary-specific treatment. Annals of Surgical Oncology. 2012; 19: 3762–3770.

[65] Cody HS 3rd. Extending ACOSOG Z0011 to Encompass Mastec-tomy: what Happens without RT? Annals of Surgical Oncology. 2017; 24: 621–623.

[66] Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. New England Journal of Medicine. 2015; 373: 317–327.

[67] Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. New England Journal of Medicine. 2015; 373: 307–316.

[68] van Roozendaal LM, de Wilt JHW, van Dalen T, van der Hage JA, Strobbe LJA, Boersma LJ, et al. The value of completion axillary treatment in sentinel node positive breast cancer patients under-going a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer. 2016; 15: 610.

[69] Tinterri C, Canavese G, Bruzzi P, Dozin B. SINODAR one, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast. 2016; 30: 197–200.

[70] de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017; 17: 379.

[71] Javid SH, He H, Korde LA, Flum DR, Anderson BO. Predictors and outcomes of completion axillary node dissection among older breast cancer patients. Annals of Surgical Oncology. 2014; 21: 2172–2180.

[72] Rudenstam C, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology. 2006; 24: 337–344.

[73] Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piro-malli D, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Annals of Surgical Oncology. 2011; 18: 125–133.

[74] Gullick WJ. Breast cancer. 2016. Available at: https://www.nc cn.org/professionals/physician_gls/pdf/breast.pdf (Accessed: 15 March 2016).

[75] Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, et al. NCCN Task Force Report: breast cancer in the older woman. Journal of the National Comprehensive Cancer Network. 2007; 6: S1–S25.

[76] Sun SX, Hollenbeak CS, Leung AM. Deviation from the Standard of Care for Early Breast Cancer in the Elderly: what are the Consequences? Annals of Surgical Oncology. 2015; 22: 2492–2499.

[77] White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Research. 2011; 13: 219.

[78] Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. Journal of the American College of Surgeons. 2006; 203: 475–480.

[79] Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2014; 32: 1365–1383.

[80] Gropper AB, Calvillo KZ, Dominici L, Troyan S, Rhei E, Economy KE, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Annals of Surgical Oncology. 2014; 21: 2506–2511.

[81] Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, et al. Breast Cancer Diagnosed during Pregnancy: Adapting recent advances in breast cancer care for pregnant patients. JAMA Oncology. 2015; 1: 1145–1153.

[82] Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B- 27. Journal of Clinical Oncology. 2008; 26: 778–785.

[83] Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of Clinical Oncology. 1997; 15: 2483–2493.

[84] van der Heidenvan der Loo M, de Munck L, Sonke GS, van Dalen T, van Diest PJ, van den Bongard HJGD, et al. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. European Journal of Cancer. 2015; 51: 915–921.

[85] Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology. 2005; 23: 2694–2702.

[86] Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using both Technetium Sulfur Colloid and Isosulfan Blue Dye. Annals of Surgery. 2001; 233: 51–59.

[87] McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. Journal of Clinical Oncology. 2000; 18: 2560–2566.

[88] Geng C, Chen X, Pan X, Li J. The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis. PLoS ONE. 2016; 11: e0162605.

[89] Classe J, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Research and Treatment. 2019; 173: 343–352.

[90] Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A review. JAMA Oncology. 2017; 3: 549–555.

[91] Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. Journal of Clinical Oncology. 2005; 23: 9304–9311.

[92] Fu JF, Chen HL, Yang J, Yi CH, Zheng S. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS ONE. 2014; 9: e105316.

[93] van Nijnatten TJA, Schipper RJ, Lobbes MBI, Nelemans PJ, Beets-Tan RGH, Smidt ML. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis. European Journal of Surgical Oncology. 2015; 41: 1278–1287.

[94] Tee SR, Devane LA, Evoy D, Rothwell J, Geraghty J, Prichard RS, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsyproven node-positive breast cancer. British Journal of Surgery. 2018; 105: 1541–1552.

[95] El Hage Chehade H, Headon H, Kasem A, Mokbel K. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pretreatment Node-positive Breast Cancer: an Update for Clinical Practice. Anticancer Research. 2016; 36: 1461–1471.

[96] Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and Resection of Clipped Node Decreases the Falsenegative Rate of Sentinel Lymph Node Surgery in Patients Presenting with Node-positive Breast Cancer (T0–T4, N1–N2) who Receive Neoadjuvant Chemotherapy. Annals of Surgery. 2016; 263: 802–807.

[97] Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients with Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. Journal of Clinical Oncology. 2016; 34: 1072–1078.

[98] Straver ME, Loo CE, Alderliesten T, Rutgers EJT, Vrancken Peeters MTFD. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. British Journal of Surgery. 2010; 97: 1226–1231.

[99] Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking Axillary Lymph Nodes with Radioactive Iodine Seeds for Axillary Staging after Neoadjuvant Systemic Treatment in Breast Cancer Patients: the MARI procedure. Annals of Surgery. 2015; 261: 378–382.

[100] van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, et al. A Novel Lessinvasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Nodepositive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clinical Breast Cancer. 2017; 17: 399–402.

[101] Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymphnode biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncology. 2013; 14: 609–618.

[102] Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Annals of Surgery. 2015; 261: 547–552.

[103] Boileau J, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsyproven node-positive breast cancer: the SN FNAC study. Journal of Clinical Oncology. 2015; 33: 258–264.

[104] Simons JM, Koppert LB, Luiten EJT, van der Pol CC, Samiei S, de Wilt JHW, et al. Deescalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Research and Treatment. 2020; 180: 725–733.

[105] Goel N, Yadegarynia S, Rodgers S, Kelly K, Collier A, Franceschi D, et al. Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease. Journal of Surgical Oncology. 2021; 124: 25–32.

[106] Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E, et al. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as her2 and TNBC? Breast Cancer Research and Treatment. 2021; 185: 657–666.

[107] Masuda N, Lee S, Ohtani S, Im Y, Lee E, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine. 2017; 376: 2147–2159.

[108] von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive her2-Positive Breast Cancer. New England Journal of Medicine. 2019; 380: 617–628.

[109] Garg AK, Buchholz TA. Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer. Annals of Surgical Oncology. 2015; 22: 1434–1440.

[110] Bear HD, McGuire KP. Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters. Annals of Surgical Oncology. 2019; 26: 2316–2318.